Should You Buy CVS Health Stock Before Feb. 10?

CVS Health will report Q4 2025 results pre-market on Feb. 10 with sell-side consensus non-GAAP EPS of $0.99 versus $1.19 in Q4 2024; investors are focused less on a potential beat than on 2026 guidance amid a proposed Medicare Advantage payment increase of only 0.9% that has already driven CVS shares down more than 14%. The Medicare-rate development pressured multiple-sensitive insurers and may weigh on CVS' Aetna outlook, though CVS' retail pharmacy and PBM businesses (and a sub-11x forward valuation versus UnitedHealth at ~16x) leave scope for a “better-than-feared” reaction if management can offset insurance headwinds in its guidance.

Analysis

Market structure: The immediate winners from the CMS Medicare Advantage (MA) rate surprise are diversified retail/PBM operators with less insurance exposure; losers are pure-play insurers (UNH) whose revenue sensitivity to MA funding is concentrated. CVS (CVS) is a hybrid — Aetna is meaningful but represents a smaller share of EBITDA than CVS’ PBM (Caremark) + retail footprint — so revenue risk is asymmetric versus UNH, which supports a relative-value thesis. Volatility: expect implied volatility on CVS options to rise 30–60% into Feb 10 earnings; insurer credit spreads (UNH) could widen 10–25 bps in the near term if guidance weakens, modestly pressuring fixed-income allocations.

Risk assessment: Tail risks include a deeper-than-proposed MA cut (>1% realized reduction vs proposal), aggressive PBM regulation, or a material pharmacy retail margin miss that could remove the valuation buffer — each could cause >20% downside for equities. Timing: immediate (days) — event volatility around Feb 10 earnings; short-term (weeks–3 months) — reaction to CMS final rule (~within 30–60 days) and UNH cadence; long-term (6–24 months) — realization of retail/PBM turnaround and Aetna synergies. Hidden dependencies: enrollment mix shifts, generic drug supply shocks, and PBM litigation outcomes can flip expected offsets quickly.

Trade implications: Direct: establish a modest long in CVS (2–3% of portfolio) ahead of Feb 10 if hedged (see below) because CVS trades <11x forward while UNH trades ~16x — valuation gap suggests upside if guidance is “better than feared.” Pair trade: long CVS 2% vs short UNH 1.5% equal-dollar to capture relative downside risk. Options: buy 30-day ATM protection (buy 1-month puts at ~8%–10% OTM) sized to cap drawdown at ~7%–9%, or sell 30–45 day 10% OTM puts to accumulate shares at lower cost if premium ≥2% of notional.

Contrarian angles: The consensus overstresses MA rate sensitivity and understates CVS’ PBM/retail insulation — the market may have overreacted on the ~14% sell-off; if CVS forward multiple reverts to 12–13x within 6–12 months, that implies ~15–25% upside versus current pricing. Historical parallels: insurers have rebounded after proposed MA rule shocks when final rules or enrollment trends softened the impact; conversely, regulatory focus on PBMs is a real binary. Actionable trigger: buy additional CVS on any post-earnings drop >10% from pre-earnings levels, but trim if CMS final reduces MA rates by >1% vs proposal.

Key Decisions for Investors

• Consider establishing a 2–3% long position in CVS (NYSE: CVS) ahead of its Feb 10 earnings but simultaneously buy 1-month puts (strike ~8–10% OTM) sized to limit portfolio loss to ~7–9% — rationale: asymmetric upside if guidance is ‘better than feared’, downside protection for event risk.
• Implement a relative-value pair trade: go long CVS (2% portfolio) and short UNH (1.5% portfolio) equal-dollar to exploit valuation spread (CVS <11x vs UNH ~16x); set stop-loss at 10% adverse move and target 12–24 month horizon for mean reversion.
• If willing to accumulate shares, sell 30–45 day 10% OTM CVS puts for premium if you can accept assignment; require premium >=2% of notional to proceed — this converts event volatility into a disciplined buy-the-dip program.
• Monitor two binary catalysts in the next 30–60 days: (1) CMS final Medicare Advantage rate decision — if final rate cut >1% vs the proposal, reduce CVS exposure by 50%; (2) UNH/insurer guidance trajectory — if UNH cuts FY26 organic margin guidance >50 bps, increase short UNH size by 25–50%.